Revisor Wealth Management LLC Invests $477,000 in Becton, Dickinson and Company (NYSE:BDX)

Revisor Wealth Management LLC bought a new stake in Becton, Dickinson and Company (NYSE:BDX - Free Report) during the 1st quarter, according to its most recent filing with the Securities and Exchange Commission (SEC). The institutional investor bought 2,085 shares of the medical instruments supplier's stock, valued at approximately $477,000.

Other institutional investors and hedge funds have also added to or reduced their stakes in the company. Brighton Jones LLC increased its position in shares of Becton, Dickinson and Company by 98.2% during the fourth quarter. Brighton Jones LLC now owns 1,770 shares of the medical instruments supplier's stock worth $401,000 after buying an additional 877 shares during the period. Hara Capital LLC boosted its position in Becton, Dickinson and Company by 26.4% during the fourth quarter. Hara Capital LLC now owns 335 shares of the medical instruments supplier's stock valued at $76,000 after acquiring an additional 70 shares during the last quarter. SBI Securities Co. Ltd. acquired a new stake in Becton, Dickinson and Company during the 4th quarter worth about $310,000. Mission Wealth Management LP bought a new position in shares of Becton, Dickinson and Company in the 4th quarter worth about $262,000. Finally, Steward Partners Investment Advisory LLC lifted its stake in shares of Becton, Dickinson and Company by 22.9% in the 4th quarter. Steward Partners Investment Advisory LLC now owns 28,142 shares of the medical instruments supplier's stock valued at $6,385,000 after purchasing an additional 5,238 shares during the period. Institutional investors and hedge funds own 86.97% of the company's stock.

Insiders Place Their Bets

In other Becton, Dickinson and Company news, EVP David Shan sold 1,166 shares of Becton, Dickinson and Company stock in a transaction on Monday, June 2nd. The shares were sold at an average price of $171.19, for a total transaction of $199,607.54. Following the transaction, the executive vice president directly owned 4,575 shares of the company's stock, valued at $783,194.25. The trade was a 20.31% decrease in their position. The transaction was disclosed in a legal filing with the Securities & Exchange Commission, which is available through the SEC website. Also, EVP Michael David Garrison sold 479 shares of the stock in a transaction dated Wednesday, April 9th. The shares were sold at an average price of $197.28, for a total transaction of $94,497.12. Following the completion of the sale, the executive vice president owned 4,887 shares of the company's stock, valued at approximately $964,107.36. This represents a 8.93% decrease in their position. The disclosure for this sale can be found here. Corporate insiders own 0.36% of the company's stock.

Analysts Set New Price Targets

A number of equities research analysts have weighed in on BDX shares. Bank of America downgraded Becton, Dickinson and Company from a "buy" rating to a "neutral" rating and set a $190.00 target price for the company. in a report on Thursday, May 1st. Citigroup downgraded shares of Becton, Dickinson and Company from a "strong-buy" rating to a "hold" rating and reduced their price objective for the stock from $217.00 to $185.00 in a research report on Thursday, May 22nd. Morgan Stanley cut their target price on shares of Becton, Dickinson and Company from $280.00 to $196.00 and set an "overweight" rating on the stock in a research note on Tuesday, May 6th. Wells Fargo & Company cut shares of Becton, Dickinson and Company from an "overweight" rating to an "equal weight" rating in a report on Thursday, May 1st. Finally, The Goldman Sachs Group lowered shares of Becton, Dickinson and Company from a "buy" rating to a "neutral" rating and set a $192.00 price objective on the stock. in a report on Friday, May 2nd. Eight equities research analysts have rated the stock with a hold rating and four have given a buy rating to the company's stock. Based on data from MarketBeat.com, the stock has a consensus rating of "Hold" and a consensus price target of $219.22.

Becton, Dickinson and Company Stock Down 0.3%

Becton, Dickinson and Company stock opened at $177.05 on Thursday. The firm has a market capitalization of $50.74 billion, a price-to-earnings ratio of 33.79, a price-to-earnings-growth ratio of 1.34 and a beta of 0.25. The firm's fifty day moving average price is $175.08 and its two-hundred day moving average price is $208.50. Becton, Dickinson and Company has a 1-year low of $163.33 and a 1-year high of $251.99. The company has a current ratio of 1.13, a quick ratio of 0.64 and a debt-to-equity ratio of 0.70.

Becton, Dickinson and Company (NYSE:BDX - Get Free Report) last posted its earnings results on Thursday, May 1st. The medical instruments supplier reported $3.35 earnings per share for the quarter, topping analysts' consensus estimates of $3.28 by $0.07. The company had revenue of $5.27 billion for the quarter, compared to analyst estimates of $5.35 billion. Becton, Dickinson and Company had a net margin of 7.28% and a return on equity of 15.99%. The firm's revenue was up 4.5% compared to the same quarter last year. During the same quarter in the prior year, the business posted $3.17 EPS. On average, equities research analysts predict that Becton, Dickinson and Company will post 14.43 earnings per share for the current fiscal year.

Becton, Dickinson and Company Dividend Announcement

The business also recently declared a quarterly dividend, which was paid on Monday, June 30th. Investors of record on Monday, June 9th were issued a dividend of $1.04 per share. The ex-dividend date was Monday, June 9th. This represents a $4.16 annualized dividend and a yield of 2.35%. Becton, Dickinson and Company's dividend payout ratio (DPR) is currently 79.39%.

Becton, Dickinson and Company Company Profile

Becton, Dickinson and Company develops, manufactures, and sells medical supplies, devices, laboratory equipment, and diagnostic products for healthcare institutions, physicians, life science researchers, clinical laboratories, pharmaceutical industry, and the general public worldwide. The company operates in three segments: BD Medical, BD Life Sciences, and BD Interventional.

Want to see what other hedge funds are holding BDX? Visit HoldingsChannel.com to get the latest 13F filings and insider trades for Becton, Dickinson and Company (NYSE:BDX - Free Report).

This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest and most accurate reporting. This story was reviewed by MarketBeat's editorial team prior to publication. Please send any questions or comments about this story to contact@marketbeat.com.